tetano
Editor, Senior Moderator
World J Gastroenterol
. 2021 Jul 14;27(26):3951-3970.
doi: 10.3748/wjg.v27.i26.3951.
Liver dysfunction and SARS-CoV-2 infection
Abraham Edgar Gracia-Ramos[SUP] 1 [/SUP], Joel Omar Jaquez-Quintana[SUP] 2 [/SUP], Raúl Contreras-Omaña[SUP] 3 [/SUP], Moises Auron[SUP] 4 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 infection is the cause of coronavirus disease 2019 (COVID-19), which predominantly affects the respiratory system; it also causes systemic and multi-organic disease. Liver damage is among the main extrapulmonary manifestations. COVID-19-associated liver injury is defined as any liver damage occurring during the disease course and treatment of COVID-19 in patients with or without pre-existing liver disease, and occurs in approximately one in five patients. Abnormal liver test results have been associated with a more severe course of COVID-19 and other complications, including death. Mechanisms linking COVID-19 to liver injury are diverse. Particular consideration should be made for patients with pre-existing liver disease, such as metabolic dysfunction-associated fatty liver disease, chronic liver disease due to viral or autoimmune disease, liver transplant carriers, or cirrhosis, given the risk for more severe outcomes. This manuscript summarizes the current lines of evidence on COVID-19-associated liver injury regarding pathophysiology, clinical significance, and management in both patients with or without pre-existing liver disease, to facilitate clinicians' access to updated information and patient care. Finally, we mention the ideas and recommendations to be considered for future research.
Keywords: COVID-19; Cirrhosis; Coronavirus; Liver; Liver diseases; Liver failure; Liver injury; SARS-CoV-2.
. 2021 Jul 14;27(26):3951-3970.
doi: 10.3748/wjg.v27.i26.3951.
Liver dysfunction and SARS-CoV-2 infection
Abraham Edgar Gracia-Ramos[SUP] 1 [/SUP], Joel Omar Jaquez-Quintana[SUP] 2 [/SUP], Raúl Contreras-Omaña[SUP] 3 [/SUP], Moises Auron[SUP] 4 [/SUP]
Affiliations
- PMID: 34326607
- PMCID: PMC8311530
- DOI: 10.3748/wjg.v27.i26.3951
Abstract
Severe acute respiratory syndrome coronavirus 2 infection is the cause of coronavirus disease 2019 (COVID-19), which predominantly affects the respiratory system; it also causes systemic and multi-organic disease. Liver damage is among the main extrapulmonary manifestations. COVID-19-associated liver injury is defined as any liver damage occurring during the disease course and treatment of COVID-19 in patients with or without pre-existing liver disease, and occurs in approximately one in five patients. Abnormal liver test results have been associated with a more severe course of COVID-19 and other complications, including death. Mechanisms linking COVID-19 to liver injury are diverse. Particular consideration should be made for patients with pre-existing liver disease, such as metabolic dysfunction-associated fatty liver disease, chronic liver disease due to viral or autoimmune disease, liver transplant carriers, or cirrhosis, given the risk for more severe outcomes. This manuscript summarizes the current lines of evidence on COVID-19-associated liver injury regarding pathophysiology, clinical significance, and management in both patients with or without pre-existing liver disease, to facilitate clinicians' access to updated information and patient care. Finally, we mention the ideas and recommendations to be considered for future research.
Keywords: COVID-19; Cirrhosis; Coronavirus; Liver; Liver diseases; Liver failure; Liver injury; SARS-CoV-2.